Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients

NCT02595255 is registered in ClinicalTrials.gov with Erasme University Hospital as lead sponsor.

NCT NCT02595255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients
Lead sponsor
Erasme University Hospital
Phase
Observational
Overall status
Recruiting
Start date
April 30, 2014
Completion date
December 31, 2041
Enrollment
275 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fertility preservation, gonadotropin-releasing hormone agonist, lymphoma, pediatrics cancer